PreveCeutical Medical Inc.
PRVCF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.45 | 0.71 | 0.48 | 0.10 |
| FCF Yield | -3.02% | -2.31% | -1.76% | -4.75% |
| EV / EBITDA | -24.70 | -18.48 | -15.53 | -15.73 |
| Quality | ||||
| ROIC | 37.33% | 51.11% | 78.81% | 75.54% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.36 | 0.23 | 0.15 | 0.25 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | -44.29% | -33.39% | 53.77% | -877.46% |
| Safety | ||||
| Net Debt / EBITDA | -5.85 | -4.30 | -3.20 | -3.51 |
| Interest Coverage | -2,484.61 | -3.11 | -4.46 | -1.92 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -21,428.75 | -13,698.81 | -27,429.34 |